siga  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Cell Signaling Technology Inc siga
    Dry powder inhalation of S-protein-loaded lung-derived exosomes elicit greater immune responses than their synthetic counterpart (A) Schematic of S protein mRNA loading into lung-derived exosomes, dry powder formulation, inhaled vaccine delivery doses, antibody production against SARS-CoV-2 spike protein, and pseudoviral challenge. Created with BioRender.com . (B) TEM images of S-Exos and S-Lipos at room temperature; scale bar: 50 nm. (C) NTA size-distribution analysis. (D) Quantification of NTA size-distribution analysis of the average mean ± standard error of five replicates; n = 1 per group. (E) Immunoblots of S protein in mouse lung lysate. (F) Quantification of immunoblots normalized to β-actin; n = 3 per group; data are represented as mean ± standard deviation. (G) <t>Anti-spike</t> <t>IgG</t> antibody titer from murine BALF detected by ELISA; n = 6 per group; data are represented as mean ± standard deviation. (H) Anti-spike <t>SIgA</t> antibody titer from murine NPLF detected by ELISA; n = 6 per group; data are represented as mean ± standard deviation. (I) Ex vivo images of PBS or pseudovirus in solution (left) and in lungs 24 h after dry powder inhalation (right). (J) Ex vivo images of S-Exo- or S-Lipo-vaccinated lungs 24 h after pseudoviral challenge.
    Siga, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/siga/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    siga - by Bioz Stars, 2023-02
    86/100 stars

    Images

    1) Product Images from "Inhalable dry powder mRNA vaccines based on extracellular vesicles"

    Article Title: Inhalable dry powder mRNA vaccines based on extracellular vesicles

    Journal: Matter

    doi: 10.1016/j.matt.2022.06.012

    Dry powder inhalation of S-protein-loaded lung-derived exosomes elicit greater immune responses than their synthetic counterpart (A) Schematic of S protein mRNA loading into lung-derived exosomes, dry powder formulation, inhaled vaccine delivery doses, antibody production against SARS-CoV-2 spike protein, and pseudoviral challenge. Created with BioRender.com . (B) TEM images of S-Exos and S-Lipos at room temperature; scale bar: 50 nm. (C) NTA size-distribution analysis. (D) Quantification of NTA size-distribution analysis of the average mean ± standard error of five replicates; n = 1 per group. (E) Immunoblots of S protein in mouse lung lysate. (F) Quantification of immunoblots normalized to β-actin; n = 3 per group; data are represented as mean ± standard deviation. (G) Anti-spike IgG antibody titer from murine BALF detected by ELISA; n = 6 per group; data are represented as mean ± standard deviation. (H) Anti-spike SIgA antibody titer from murine NPLF detected by ELISA; n = 6 per group; data are represented as mean ± standard deviation. (I) Ex vivo images of PBS or pseudovirus in solution (left) and in lungs 24 h after dry powder inhalation (right). (J) Ex vivo images of S-Exo- or S-Lipo-vaccinated lungs 24 h after pseudoviral challenge.
    Figure Legend Snippet: Dry powder inhalation of S-protein-loaded lung-derived exosomes elicit greater immune responses than their synthetic counterpart (A) Schematic of S protein mRNA loading into lung-derived exosomes, dry powder formulation, inhaled vaccine delivery doses, antibody production against SARS-CoV-2 spike protein, and pseudoviral challenge. Created with BioRender.com . (B) TEM images of S-Exos and S-Lipos at room temperature; scale bar: 50 nm. (C) NTA size-distribution analysis. (D) Quantification of NTA size-distribution analysis of the average mean ± standard error of five replicates; n = 1 per group. (E) Immunoblots of S protein in mouse lung lysate. (F) Quantification of immunoblots normalized to β-actin; n = 3 per group; data are represented as mean ± standard deviation. (G) Anti-spike IgG antibody titer from murine BALF detected by ELISA; n = 6 per group; data are represented as mean ± standard deviation. (H) Anti-spike SIgA antibody titer from murine NPLF detected by ELISA; n = 6 per group; data are represented as mean ± standard deviation. (I) Ex vivo images of PBS or pseudovirus in solution (left) and in lungs 24 h after dry powder inhalation (right). (J) Ex vivo images of S-Exo- or S-Lipo-vaccinated lungs 24 h after pseudoviral challenge.

    Techniques Used: Derivative Assay, Western Blot, Standard Deviation, Enzyme-linked Immunosorbent Assay, Ex Vivo